Chicago—Any questions regarding the safety of tranexamic acid in patients undergoing cardiac surgery seem to have been put to rest with the ATACAS (Aspirin and Tranexamic Acid For Coronary Artery Surgery) trial. In a cohort of nearly 5,000 patients, the trial concluded that tranexamic acid was associated with a lower risk for bleeding than placebo, without a higher risk for death or thrombotic complications during the first 30 postoperative days.
“There are risk factors involved in